[HTML][HTML] An overview of PARP inhibitors for the treatment of breast cancer
Loss-of-function mutations in BRCA1 and BRCA2 are detected in at least 5% of unselected
patients with breast cancer (BC). These BC susceptibility genes encode proteins critical for …
patients with breast cancer (BC). These BC susceptibility genes encode proteins critical for …
PARP and PARG inhibitors in cancer treatment
D Slade - Genes & development, 2020 - genesdev.cshlp.org
Oxidative and replication stress underlie genomic instability of cancer cells. Amplifying
genomic instability through radiotherapy and chemotherapy has been a powerful but …
genomic instability through radiotherapy and chemotherapy has been a powerful but …
[HTML][HTML] Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Background The randomized, double-blind OlympiA trial compared 1 year of the oral poly
(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as …
(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as …
TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes
PURPOSE Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved
for the treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic …
for the treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic …
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Background Poly (adenosine diphosphate–ribose) polymerase inhibitors target cancers with
defects in homologous recombination repair by synthetic lethality. New therapies are …
defects in homologous recombination repair by synthetic lethality. New therapies are …
Epidemiology of triple-negative breast cancer: a review
FM Howard, OI Olopade - The Cancer Journal, 2021 - journals.lww.com
Triple-negative breast cancer accounted for 12% of breast cancers diagnosed in the United
States from 2012 to 2016, with a 5-year survival 8% to 16% lower than hormone receptor …
States from 2012 to 2016, with a 5-year survival 8% to 16% lower than hormone receptor …
Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses
Breast cancer susceptibility variants frequently show heterogeneity in associations by tumor
subtype,–. To identify novel loci, we performed a genome-wide association study including …
subtype,–. To identify novel loci, we performed a genome-wide association study including …
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Background Olaparib is an oral poly (adenosine diphosphate–ribose) polymerase inhibitor
that has promising antitumor activity in patients with metastatic breast cancer and a germline …
that has promising antitumor activity in patients with metastatic breast cancer and a germline …
[HTML][HTML] Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis
R Yoshida - Breast Cancer, 2021 - Springer
Breast cancer is a common cancer affecting a large number of patients. Notably, 5–10% of
all breast cancer patients are genetically predisposed to cancers. Although the most …
all breast cancer patients are genetically predisposed to cancers. Although the most …
Management of hereditary breast cancer: American society of clinical oncology, American society for radiation oncology, and society of surgical oncology guideline
NM Tung, JC Boughey, LJ Pierce… - Journal of clinical …, 2020 - ascopubs.org
PURPOSE To develop recommendations for management of patients with breast cancer
(BC) with germline mutations in BC susceptibility genes. METHODS The American Society …
(BC) with germline mutations in BC susceptibility genes. METHODS The American Society …